Reported Late Monday, Atlas Lithium Corporation Announces Pricing Of $4.05M Underwritten Public Offering Of 675,000 Shares Of Common Stock At A Price Of $6.00/Share; To Be Listed On The Nasdaq Under Ticker Symbol “ATLX” In January 10 Up-Listing

Belo Horizonte, Brazil–(Newsfile Corp. – January 9, 2023) – Atlas Lithium Corporation (NASDAQ:ATLX) ("Atlas Lithium" or the "Company"), a U.S. mineral exploration and mining company with

Belo Horizonte, Brazil–(Newsfile Corp. – January 9, 2023) – Atlas Lithium Corporation (NASDAQ:ATLX) (“Atlas Lithium” or the “Company”), a U.S. mineral exploration and mining company with lithium projects and properties in other critical battery metals, today announced the pricing of its underwritten public offering of 675,000 shares of common stock at a public offering price of $6.00 per share, for aggregate gross proceeds of approximately $4.05 million, prior to deducting underwriting discounts, commissions, and other offering expenses. The Company has granted the underwriters a 45-day option to purchase up to an additional 101,250 shares at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any. The offering is expected to close on or about January 12, 2023, subject to satisfaction of customary closing conditions.

Atlas Lithium has received approval to list its common stock on the Nasdaq Capital Market under the symbol “ATLX” with trading expected to begin on January 10, 2023.

EF Hutton, division of Benchmark Investments, LLC, is acting as sole book-running manager for the offering.

A registration statement on Form S-1, as amended (File No. 333-262399), was filed with the Securities and Exchange Commission (“SEC”) and was declared effective on January 9, 2023. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus relating to this offering, when available, may be obtained from EF Hutton, division of Benchmark Investments, LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@efhuttongroup.com or telephone at (212) 404-7002.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Total
0
Shares
Related Posts
Read More

Sanofi, Regeneron Announced Dupixent Phase 3 Trial in Children 1 to 11 Years of Age With Eosinophilic Esophagitis Met Its Primary Endpoint of Histological Disease Remission at 16 Weeks With Both Higher and Lower Dose Weight-tiered Regimens

A Phase 3 trial assessing the investigational use of Dupixent® (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE) met its primary endpoint of histological disease remission at 16 weeks with both higher and lower dose weight-tiered regimens. There are no approved treatments for children with EoE under 12 years of age. Naimish Patel, M.D.

REGN